By Pooja Babbrah, Senior Consultant In January 2017, the Food and Drug Administration (FDA) released the Final Rule for Biosimilar Naming. In this final rule, the FDA spelled out the …
By Pooja Babbrah, Senior Consultant Stakeholders across the industry are debating potential costs and burden associated with implementing the new, nonproprietary naming convention for biologics and biosimilars. Requirements for the …
By Pooja Babbrah, Senior Consultant The Food and Drug Administration (FDA) recently issued two new rules that significantly affect biologics and biosimilars. The first rule spells out the naming conventions …
By Brian Bamberger, Practice Lead, Life Sciences Biologics and biosimilars are starting to burst into the American market. Biosimilars are expected to quickly become mainstream in the near future because …
By Connie Sinclair, Director, Regulatory Resource Center Biosimilars are starting to enter the market in the United States and are generating interest because of their significant cost-savings potential and patient …
By Tony Schueth Biosimilars now are being introduced in the United States and are expected to rapidly become lower-cost, mainstream treatments for a range of chronic diseases, including cancer, rheumatoid …
By Tony Schueth, CEO & Managing Partner Biosimilars now are set to hit the US market with the recent recommendation that the government approve Novartis’s Zarxio cancer drug as a …